NEURACEQ

This brand name is authorized in United States. It is also authorized in Austria, Croatia, Estonia, France, Ireland, Italy, Lithuania, Poland, Spain.

Active ingredients

The drug NEURACEQ contains one active pharmaceutical ingredient (API):

1	Florbetaben ¹⁸F UNII TLA7312TOI - FLORBETABEN F-18
	Florbetaben ¹⁸F binds to β-amyloid neuritic plaques in the brain. It is a radiopharmaceutical indicated for Positron Emission Tomography (PET) imaging of β-amyloid neuritic plaque density in the brains of adult patients with cognitive impairment who are being evaluated for Alzheimer’s disease (AD) and other causes of cognitive impairment.
	Read more about Florbetaben ¹⁸F

Medication package inserts

Below package inserts are available for further reading:

Document	Type	Information Source
NEURACEQ Solution for injection	MPI, US: SPL/PLR	FDA, National Drug Code (US)

Medicine classification

This drug has been classified in the anatomical therapeutic chemical (ATC) classification system as follows:

ATC Group		Classification
V09AX06		V Various → V09 Diagnostic radiopharmaceuticals → V09A Central nervous system → V09AX Other central nervous system diagnostic radiopharmaceuticals
Discover more medicines within V09AX06

Authorization and marketing

This drug has been assigned below unique identifiers within the countries it is being marketed:

Country	Identification scheme	Identifier(s)
EE	Ravimiamet	1642430
ES	Centro de información online de medicamentos de la AEMPS	113906001
FR	Base de données publique des médicaments	69854597
IT	Agenzia del Farmaco	043301011
LT	Valstybinė vaistų kontrolės tarnyba	1072847
PL	Rejestru Produktów Leczniczych	100322663
US	FDA, National Drug Code	54828-001